Sanofi and Regeneron have pledged to make Praluent more accessible to patients as data show that the drug significantly cut the risk of cardiovascular events in high-risk patients.
Sanofi and Regeneron have unveiled new data further backing the safety and efficacy of PCSK9 inhibitor Praluent in lowering cholesterol in patients with diabetes.